Celsion and Medidata to Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients to be presented at 2022 AACR Annual Meeting being held April 8-13 in New Orleans, LA LAWRENCEVILLE, N.J., April...

Celsion’s OVATION 1 Study with GEN-1 in Ovarian Cancer Shows Strong Progression-Free Survival Treatment Effect Utilizing Medidata Synthetic Control Arm Hazard Ratio of 0.53 for PFS in the Phase I Intent-To-Treat Population Synthetic Randomization Provides Means to Evaluate Strategies to Accelerate GEN-1 Clinical Program for Newly Diagnosed Stage...

Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Medidata Solutions (NASDAQ: MDSO) on Behalf of Medidata Shareholders and Encourages Medidata Investors to Contact the Firm NEW YORK, June 12, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Medidata Solutions (NASDAQ: MDSO) on behalf of...